Bank of New York Mellon Corp Purchases 13,069 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Bank of New York Mellon Corp lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.4% during the second quarter, Holdings Channel.com reports. The institutional investor owned 934,404 shares of the company’s stock after acquiring an additional 13,069 shares during the quarter. Bank of New York Mellon Corp’s holdings in Neurocrine Biosciences were worth $128,639,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. First Horizon Advisors Inc. grew its position in shares of Neurocrine Biosciences by 10.5% during the 4th quarter. First Horizon Advisors Inc. now owns 782 shares of the company’s stock worth $103,000 after buying an additional 74 shares in the last quarter. Quadrant Capital Group LLC grew its position in shares of Neurocrine Biosciences by 3.9% during the 4th quarter. Quadrant Capital Group LLC now owns 2,075 shares of the company’s stock worth $273,000 after buying an additional 78 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its position in shares of Neurocrine Biosciences by 3.2% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,530 shares of the company’s stock worth $333,000 after buying an additional 78 shares in the last quarter. Commonwealth Equity Services LLC boosted its position in Neurocrine Biosciences by 0.6% during the first quarter. Commonwealth Equity Services LLC now owns 13,941 shares of the company’s stock valued at $1,923,000 after purchasing an additional 84 shares in the last quarter. Finally, Balentine LLC grew its stake in Neurocrine Biosciences by 4.0% in the fourth quarter. Balentine LLC now owns 2,316 shares of the company’s stock valued at $305,000 after purchasing an additional 89 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Trading Down 0.4 %

Shares of NASDAQ:NBIX opened at $152.27 on Tuesday. Neurocrine Biosciences, Inc. has a 12-month low of $103.63 and a 12-month high of $157.98. The company has a market capitalization of $15.32 billion, a PE ratio of 41.95 and a beta of 0.37. The business has a 50 day moving average of $143.90 and a two-hundred day moving average of $139.40.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). The company had revenue of $590.20 million during the quarter, compared to analyst estimates of $545.98 million. Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The company’s revenue was up 30.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.95 earnings per share. Equities research analysts predict that Neurocrine Biosciences, Inc. will post 4.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. StockNews.com upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Sunday, August 4th. Evercore ISI assumed coverage on Neurocrine Biosciences in a research note on Tuesday, May 14th. They set an “outperform” rating and a $175.00 price target on the stock. JPMorgan Chase & Co. boosted their price target on Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. BMO Capital Markets boosted their price target on Neurocrine Biosciences from $129.00 to $138.00 and gave the stock a “market perform” rating in a research note on Thursday, May 2nd. Finally, Robert W. Baird boosted their price target on Neurocrine Biosciences from $157.00 to $180.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Six research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and an average price target of $161.32.

Insider Transactions at Neurocrine Biosciences

In other news, Director Stephen A. Sherwin sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total transaction of $5,338,400.00. Following the completion of the transaction, the director now directly owns 26,504 shares of the company’s stock, valued at approximately $3,537,223.84. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, insider Ingrid Delaet sold 273 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $147.70, for a total transaction of $40,322.10. Following the completion of the sale, the insider now directly owns 6,607 shares in the company, valued at $975,853.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Stephen A. Sherwin sold 40,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total value of $5,338,400.00. Following the sale, the director now owns 26,504 shares of the company’s stock, valued at $3,537,223.84. The disclosure for this sale can be found here. Insiders sold a total of 111,798 shares of company stock valued at $16,014,496 in the last three months. 4.30% of the stock is currently owned by company insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.